Clinical Overview
Silodosin Capsules (4mg, 8mg) is an ultra-selective alpha-1A adrenergic receptor antagonist on the PMBI formulary. It demonstrates an extraordinarily high alpha-1A to alpha-1B binding affinity ratio (162:1), targeting the lower urinary tract smooth muscle with surgical precision while sparing vascular alpha-1B receptors that regulate arterial blood pressure. This confers excellent cardiovascular safety and minimal postural hypotension. Indicated for the treatment of the signs and symptoms of Benign Prostatic Hyperplasia (BPH) in adult men.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily with a meal (8 mg once daily with dinner; 4 mg once daily in moderate renal impairment CrCl 30-50 mL/min) with a glass of water. Swallow whole.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Retrograde ejaculation (anejaculation occurring in up to 28% of patients), dizziness, diarrhea, orthostatic dizziness, nasopharyngitis. Rare/Severe: Intraoperative Floppy Iris Syndrome (IFIS) and priapism.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
High incidence of retrograde ejaculation; counsel patients that semen enters the bladder during climax without affecting sexual pleasure or orgasmic function. Contraindicated in severe renal impairment (CrCl < 30 mL/min) and severe hepatic impairment (Child-Pugh C). Contraindicated with strong CYP3A4 inhibitors (clarithromycin, ketoconazole).
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, nephrological diagnosis, or urological treatment recommendations. Always consult a registered nephrologist, urologist, or qualified medical practitioner before initiating, modifying, or discontinuing any kidney or urinary tract medication.
Silodosin Capsules 4 mg
Silodosin Capsules (4mg, 8mg) is an ultra-selective alpha-1A adrenergic receptor antagonist on the PMBI formulary. It demonstrates an extraordinarily high alpha-1A to alpha-1B binding affinity ratio (162:1), targeting the lower urinary tract smooth muscle with surgical precision while sparing vascular alpha-1B receptors that regulate arterial blood pressure. This confers excellent cardiovascular safety and minimal postural hypotension. Indicated for the treatment of the signs and symptoms of Benign Prostatic Hyperplasia (BPH) in adult men.
Silodosin 4mg + Dutasteride 0.5mg Capsules
Silodosin (4mg/8mg) and Dutasteride (0.5mg) Capsules is an advanced fixed-dose combination for Benign Prostatic Hyperplasia (BPH). Silodosin is an ultra-selective alpha-1A adrenergic receptor antagonist (>160-fold selectivity over alpha-1B receptors), providing targeted bladder neck and prostatic relaxation with minimal vascular hypotensive effects. Dutasteride blocks both 5-alpha reductase isoforms, permanently lowering circulating and intraprostatic DHT to shrink prostate gland tissue. Indicated for treatment of moderate-to-severe LUTS associated with prostatic enlargement.
Silodosin 8mg + Dutasteride 0.5mg Capsules
Silodosin (4mg/8mg) and Dutasteride (0.5mg) Capsules is an advanced fixed-dose combination for Benign Prostatic Hyperplasia (BPH). Silodosin is an ultra-selective alpha-1A adrenergic receptor antagonist (>160-fold selectivity over alpha-1B receptors), providing targeted bladder neck and prostatic relaxation with minimal vascular hypotensive effects. Dutasteride blocks both 5-alpha reductase isoforms, permanently lowering circulating and intraprostatic DHT to shrink prostate gland tissue. Indicated for treatment of moderate-to-severe LUTS associated with prostatic enlargement.